Knopp Biosciences LLC today announced that it had completed a Class C equity financing of approximately $14 million led by Solas BioVentures, whose managing director, C. David Adair, M.D., was elected to the Knopp Board of Managers.



Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for developmental and epileptic encephalopathies, other rare epilepsies, neuropathic pain, and tinnitus. Please visit www.knoppbio.com.


Knopp Biosciences Completes Class C Financing and Elects David Adair to Board of Managers

Description

Company Information

Related People

Knopp Biosciences Completes Class C Financing and Elects David Adair to Board of Managers

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Company Information